A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma

World Journal of Urology

Volumn 28, Issue 4, 2010, Pages 479-485

  Arum, Carl Jørgen ^a,b   Kodama, Yosuke ^a   Rolim, Natale ^a   Widerøe, Marius ^a   Anderssen, Endre ^a   Viset, Trond ^b   Otterlei, Marit ^a   Lundgren, Steinar ^a,b   Chen, Duan ^a   Zhao, Chun Mei ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bladder cancer; Rat models; siRNA delivery; siRNA targets

Indexed keywords

FLUORESCENT DYE; SMALL INTERFERING RNA;

ANIMAL; ARTICLE; BIOPSY; BLADDER TUMOR; DISEASE MODEL; FEMALE; FISCHER 344 RAT; GENE THERAPY; GENE TRANSFER; GENETICS; INTRAVESICAL DRUG ADMINISTRATION; METHODOLOGY; PATHOLOGY; RAT; TUMOR CELL LINE; PROCEDURES; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BIOPSY; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT DYES; GENE THERAPY; GENE TRANSFER TECHNIQUES; RATS; RATS, INBRED F344; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS; GENETIC THERAPY;

EID: 77954862636     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0542-6     Document Type: Article

References (26)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669): 806-811. doi: 10. 1038/35888.
2. Fire AZ (2007) Gene silencing by double-stranded RNA (Nobel lecture). Angew Chem Int Ed Engl 46(37): 6966-6984. doi: 10. 1002/anie. 200701979.
3. Reischl D, Zimmer A (2009) Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine 5(1): 8-20. doi: 10. 1016/j. nano. 2008. 06. 001.
4. Bantounas I, Phylactou LA, Uney JB (2004) RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33(3): 545-557. doi: 10. 1677/jme. 1. 01582.
5. Gondi CS, Rao JS (2009) Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol 220(2): 285-291. doi: 10. 1002/jcp. 21790.
6. Akhtar S, Benter IF (2007) Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117(12): 3623-3632. doi: 10. 1172/JCI33494.
7. Oh YK, Park TG (2009) siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61(10): 850-862. doi: 10. 1016/j. addr. 2009. 04. 018.
8. Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl (218): 12-20.
9. Bryan GT (1977) The pathogenesis of experimental bladder cancer. Cancer Res 37(8): 2813-2816.
10. Williams PD, Lee JK, Theodorescu D (2008) Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia 10(8): 838-846.
11. Arum CJ, Anderssen E, Tommeras K, Lundgren S, Chen D, Zhao CM (2010) Gene expression profiling and pathway analysis of superficial bladder cancer in rats. Urology 75(3): 742-749. doi: 10. 1016/j. urology. 2009. 03. 008.
12. Reis LO, Pereira TC, Favaro WJ, Cagnon VH, Lopes-Cendes I, Ferreira U (2009) Experimental animal model and RNA interference: a promising association for bladder cancer research. World J Urol 27(3): 353-361. doi: 10. 1007/s00345-009-0374-4.
13. Ito N, Fukushima S, Shirai T, Nakanishi K, Hasegawa R, Imaida K (1983) Modifying factors in urinary bladder carcinogenesis. Environ Health Perspect 49: 217-222.
14. King EB, Vanderlaan M, Jensen RH, Kromhout LK, Hoffman JW (1984) Morphologic changes in rat urothelial cells during carcinogenesis: I. Histologic and cytologic changes. Cytometry 5(5): 447-453. doi: 10. 1002/cyto. 990050503.
15. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I, Moore RB (1999) Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 81(4): 638-646. doi: 10. 1038/sj. bjc. 6690741.
16. Mengual L, Burset M, Ars E, Lozano JJ, Villavicencio H, Ribal MJ, Alcaraz A (2009) DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol 182(2): 741-748. doi: 10. 1016/j. juro. 2009. 03. 084.
17. Yao R, Yi Y, Clinton GJ, Lubetz RA, You M (2007) Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 9(3): 207-221. doi: 10. 1593/neo. 06814.
18. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4; 14)-positive multiple myeloma in mice. J Clin Invest 119(5): 1216-1229. doi: 10. 1172/JCI38017.
19. Sweeney P, Karashima T, Ishikura H, Wiehle S, Yamashita M, Benedict WF, Cristiano RJ, Dinney CP (2003) Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. Cancer Res 63(14): 4017-4020.
20. Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA, Kjems J (2009) The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17(7): 1225-1233. doi: 10. 1038/mt. 2009. 91.
21. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T, Okada Y, Maekawa T (2005) Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 115(4): 978-985. doi: 10. 1172/JCI23043.
22. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11(3): 263-270. doi: 10. 1038/nm1191.
23. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23(4): 457-462. doi: 10. 1038/nbt1081.
24. Sioud M (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348(5): 1079-1090. doi: 10. 1016/j. jmb. 2005. 03. 013.
25. Robbins M, Judge A, MacLachlan I (2009) siRNA and innate immunity. Oligonucleotides 19(2): 89-101. doi: 10. 1089/oli. 2009. 0180.
26. Herr HW, Morales A (2008) History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 179(1): 53-56. doi: 10. 1016/j. juro. 2007. 08. 122.